Posted by Michael Wonder on 03 Nov 2016
Tesaro announces submission of niraparib new drug application for platinum-sensitive, recurrent ovarian cancer
1 November 2016 - Teasro today announced that it has completed the niraparib rolling new drug application submission to the U.S. FDA for the maintenance treatment of patients with platinum-sensitive, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response to platinum-based chemotherapy.
Niraparib is an oral, once-daily PARP inhibitor that is currently being evaluated in three pivotal trials.
